| Popis: |
Idiopathic inflammatory myopathies (IIM) of childhood are rare serious disorders, of which the most common is juvenile dermatomyositis (JDM). It is recognized increasingly that, even within JDM, there is significant heterogeneity. Recently defined biomarkers, such as the myositis-specific autoantibodies (MSA) have been valuable to define juvenile IIM subgroups and may provide novel methods of classification. Although randomized controlled trials in JDM are challenging, an increasing consensus-based body of evidence is being used to drive standardization of treatment and care, with new drugs for severe cases being increasingly tested. Significant differences between adults and children with dermatomyositis (DM) exist, and are reviewed in this chapter. These differences emphasize the importance of specialists in the area of transition of young people who have had JDM to receive their care from a team of health professionals with comprehensive knowledge of JDM, as well as transitional care issues. |
